Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 3 | EJNMMI Radiopharmacy and Chemistry

Fig. 3

From: [225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts

Fig. 3

A Surviving fraction (SF) of HER2-positive human BC cells exposed in vitro to medium, DOTA-trasuzumab, [225Ac]Ac-DOTA-trastuzumab labeled at increasing SA (0.148–1.665 kBq/µg) or [225Ac]Ac-DOTA-trastuzumab (SA = 1.665 kBq/µg) combined with a 100-fold excess of DOTA-trastuzumab to block HER2. Values shown are the mean ± SD (n = 6–12). Significant differences (****P ≤ 0.0001) are indicated by the asterisks. B SF versus dose in SK-BR-3 cells estimated by cellular dosimetry. The curve was fitted to a linear quadratic model. The estimated dose to decrease the SF to 0.10 (dotted line) was 1.10 Gy

Back to article page